Truqap(capivasertib)

[indications for Truqap]

Truqap is a kinase inhibitor, which is used in combination with fulvestrant to treat adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer. According to FDA-approved tests, these patients have one or more PIK3CA/AKT1/PTEN mutations, which progress after receiving at least one endocrine-based regimen for metastatic diseases, or relapse within 12 months after completing adjuvant therapy.

[Truqap Dosage and Administration]

Based on the existence of one or more of the following gene changes in tumor tissue, Truqap was selected to treat patients with advanced or metastatic breast cancer with HR positive and HER2 negative: PIK3CA/AKT1/PTEN.

Recommended dosage: take 400mg orally twice a day, with food or alone for 4 days, and then stop taking the medicine for 3 days.

[Contraindications to Truqap]

Severe allergic reaction to Truqap or any of its components.

[Truqap is used in special people]

Breastfeeding: It is not recommended to breastfeed.

[Truqap drug interaction]

Powerful CYP3A inhibitors: Avoid combination. If combined use cannot be avoided, reduce the dose of Truqap.

Moderate CYP3A inhibitor: Reduce the dose of Truqap.

Strong and moderate CYP3A inducers: Avoid combination.

[Truqap Warnings and Precautions]

Hyperglycemia: regularly evaluate blood sugar levels before and during treatment. According to the severity, suspend, reduce the dose or permanently stop Truqap.

Diarrhea: Truqap causes diarrhea in most patients. Advise patients to increase oral liquid and start antidiarrheal treatment. If diarrhea occurs during taking Truqap, please consult medical staff. According to the severity, suspend, reduce the dose or permanently stop Truqap.

Adverse skin reactions: Monitor the following symptoms and signs of adverse skin reactions. According to the severity, suspend, reduce the dose or permanently stop Truqap.

Embryo-fetal toxicity: Truqap can cause fetal injury. Inform patients of the potential risks to the fetus and take effective contraceptive measures. For information about pregnancy and contraception, please refer to the complete prescription information of fulvestrant.

[Adverse reaction of Truqap]

The most common adverse reactions (incidence ≥20%) include laboratory abnormalities, including diarrhea, skin adverse reactions, random blood sugar increase, lymphopenia, hemoglobin decrease, fasting blood sugar increase, nausea, fatigue, leukopenia, triglyceride increase, neutropenia, creatinine increase, vomiting and stomatitis.